Physician profile
Usman Hashmi
NPI 1922334556
$4,670.61
in general payments reported to CMS, 2019-2025
30 companies · $980 in 2025
The $980 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $134 · 2021: $91.42 · 2022: $417 · 2023: $848 · 2024: $432 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.83 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,618.90 | 2019-2023 | Penumbra System |
| Abbott Laboratories | $795.10 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision, Xience Skypoint |
| Medtronic, INC. | $284.84 | 2021-2025 | Symplicity G3, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $241.48 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.55 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $184.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.22 | 2019-2025 | Farxiga, Lokelma |
| Ekos Corporation | $154.46 | 2019 | |
| Merck Sharp & Dohme LLC | $104.33 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $99.05 | 2024-2025 | Onpattro, Amvuttra |
| Stryker Corporation | $91.68 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $73.87 | 2023-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Ekosonic |
| Pfizer INC. | $55.29 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.63 | 2022-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $48.55 | 2024-2025 | Kengreal, Cleviprex |
| Bard Peripheral Vascular, INC. | $43.17 | 2023 | Venclose Maven Catheter, Venovo |
| Edwards Lifesciences Corporation | $40.40 | 2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $29.89 | 2025 | Repatha |
| Azurity Pharmaceuticals, INC. | $29.44 | 2024-2025 | Edarbyclor |
| Kestra Medical Technology Services, INC. | $29.26 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $27.73 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $27.01 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $25.32 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $23.88 | 2023 | Ozempic, Rybelsus |
| Impulse Dynamics (USA) INC. | $20.26 | 2022 | |
| Cvrx, INC. | $19.39 | 2022 | |
| Medicomp INC | $17.51 | 2023 | Telepatch Cardiac Monitor |
| Inspire Medical Systems, INC. | $17.39 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $16.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.